An interventional study of Probiotic Agent and Probiotic Agent in Immune Surveillance, sponsored by Natural Immune Systems Inc. Completed at 1 site in United States. Open to participants aged 18 Years to 75 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-11-13.
Sponsored by Natural Immune Systems Inc · Not applicable, Interventional, and Basic science
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Clinical proof-of-concept study, comparing the acute immune impacts of 3 doses of a probiotic strain to a placebo.
The initial four-participant module evaluated all 3 planned probiotic doses. The subsequent eight-participant module evaluated only the lowest and highest doses; consequently, the intermediate dose was administered to four participants only.
This study involved twelve participants, composed of healthy adults, who consumed a placebo and different doses of the probiotic at different times. Testing for immune status and cytokine levels was conducted to determine the acute impact of the probiotic on immune function when compared to a placebo.
Clinical proof-of-concept study comparing the acute immune effects of different doses of a probiotic compared to a placebo. The probiotic strain is characterized as Bacillus coagulans JBI-YZ6.3 (BC4U).
12 subjects participated in a placebo-controlled, escalating dose, cross-over study design, wherein they consumed placebo, dose 1, (dose 2: only initial module of N=4), and dose 3, each separated by a 1-week washout period.
Blood samples were taken 1 hour after participants arrived; the dose was then administered. Samples were taken 1 hour, 2 hours, and 3 hours following administration.
A series of immune panels were used to determine the acute impacts on immune surveillance, immune cell activation status, immune cell priming, and cytokine profiles.
Natural Immune Systems Inc is the lead sponsor of 25 studies on the registry; 6 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Willing to comply with study procedures, including:
Exclusion Criteria:
Crossover study: Participants consumed placebo on the first clinic visit, a low dose of the probiotic on the second clinic visit, (a medium dose of the probiotic on the third clinic visit (only the first 4 participants), and a high dose of the probiotic on the final clinic visit. Each clinic visit was separated by at least 1 week wash-out period.
Dietary Supplement: Probiotic Agent
Bacillus coagulans JBI-YZ6.3 (BC4U)
An escalating dose cross-over design: Participants are fed 0 mg, 100 mg, 200 mg, and 400 mg on different clinic visits.
Immune communication
Changes in serum cytokine levels
Time frame: 3 hours
Immune surveillance and alertness
Changes in immune cell trafficking and status of immune cell alertness, ie. the changes in immune cell populations and activation status following consumption: Numbers of CD3- CD56+ NK cells in blood Numbers of CD3+ CD56+ NKT cells in blood Numbers of CD3+ CD56- T cells in blood Numbers of cells positive for CD25 Numbers of cells positive for CD69
Time frame: 3 hours
Immune responsiveness
Ex vivo immune challenges, documenting the capabilities of anti-bacterial and anti-viral immune responses: Cytokine levels in 24-hour culture supernatants of ex vivo immune cell cultures in unchallenged cultures Cytokine levels in 24-hour culture supernatants of ex vivo immune cell cultures in lipopolysaccharide-inflamed cultures Cytokine levels in 24-hour culture supernatants of ex vivo immune cell cultures in Poly I:C challenged cultures
Time frame: 3 hours
Plan to share: No
No publications or documents are linked to this record.
Ran from Nov 2024 to primary completion in Sep 2025, 10 months.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Natural Immune Systems Inc